| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
SOD1 (superoxide dismutase 1). NUCC-0000323 is a small-molecule inhibitor of SOD1 expression. It functions by reducing intracellular SOD1 protein levels rather than directly inhibiting the enzyme's catalytic activity. Since SOD1 mutations and overexpression are closely associated with the pathogenesis of amyotrophic lateral sclerosis (ALS), NUCC-0000323 is being researched as a potential therapeutic strategy to reduce neurotoxicity and slow disease progression by downregulating SOD1 expression.
|
|---|---|
| ln Vitro |
NUCC-0000323 is a potent SOD1 expression inhibitor. It reduces intracellular SOD1 protein levels, thereby decreasing the cellular burden of mutant or overexpressed SOD1. This mechanism is being explored as a therapeutic strategy for amyotrophic lateral sclerosis (ALS), where SOD1 mutations and overexpression contribute to neurotoxicity and disease progression. The compound's activity is characterized by its ability to lower SOD1 protein levels in cells.
|
| ln Vivo |
In vivo, NUCC-0000323 is being researched as a potential therapeutic strategy for amyotrophic lateral sclerosis (ALS) by reducing SOD1 expression and thereby alleviating neurotoxicity and slowing disease progression. Its in vivo efficacy would be evaluated in animal models of ALS, such as SOD1-G93A transgenic mice, where disease progression, motor function, and survival would be assessed.
|
| Enzyme Assay |
In vitro binding and functional assays for NUCC-0000323 involve treating cells with the compound and measuring its effects on SOD1 protein levels. Western blot analysis or ELISA-based assays are used to quantify SOD1 expression in cells treated with increasing concentrations of the compound. The compound's ability to reduce SOD1 protein levels is the primary readout for its biological activity.
|
| Cell Assay |
Cellular assays for NUCC-0000323 are performed using cell lines or primary neurons that express mutant or wild-type SOD1. Cells are treated with increasing concentrations of the compound (typically in the micromolar range), and SOD1 protein levels are measured by Western blot or ELISA. The reduction in SOD1 expression is assessed, and the compound's ability to protect against SOD1-mediated neurotoxicity can be evaluated by measuring cell viability and markers of oxidative stress.
|
| Animal Protocol |
In vivo efficacy of NUCC-0000323 would be evaluated in animal models of amyotrophic lateral sclerosis (ALS), such as the SOD1-G93A transgenic mouse model. The compound would be administered via injection (intraperitoneal or subcutaneous), and disease progression would be monitored by assessing motor function (e.g., rotarod performance, grip strength), survival, and neuropathological changes (e.g., motor neuron loss, SOD1 aggregation).
|
| ADME/Pharmacokinetics |
NUCC-0000323 has a molecular formula of C15H13BrN4S and a molecular weight of 361.26. It is supplied as a solid (off-white to light yellow) with solubility in DMSO of 125 mg/mL (346.01 mM). The compound should be stored at 4°C, protected from light, and in solvent at -80°C for 6 months or at -20°C for 1 month. It is for research use only and is not intended for human therapeutic use.
|
| Toxicity/Toxicokinetics |
No specific toxicity data is available for NUCC-0000323. As a SOD1 expression inhibitor being researched for ALS, its safety profile would be an important consideration. Potential toxicities could be related to the reduction of SOD1 activity in normal tissues, as SOD1 plays a critical role in antioxidant defense. Standard preclinical safety studies would be required to evaluate its safety for potential therapeutic applications.
|
| References | |
| Additional Infomation |
NUCC-0000323 (CAS#: 663212-78-0) is a potent small-molecule inhibitor of SOD1 expression. It has a molecular formula of C15H13BrN4S and a molecular weight of 361.26. The compound is being researched for amyotrophic lateral sclerosis (ALS) by reducing SOD1 protein levels to alleviate neurotoxicity and slow disease progression. It is an investigational compound and is not approved for clinical use.
|
| Molecular Formula |
C15H13BRN4S
|
|---|---|
| Molecular Weight |
361.26
|
| Exact Mass |
360.004
|
| CAS # |
663212-78-0
|
| PubChem CID |
1296639
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
560.8±60.0 °C at 760 mmHg
|
| Flash Point |
292.9±32.9 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.697
|
| LogP |
4.15
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
21
|
| Complexity |
319
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN1C(=NN=C1SCC2=CC=C(C=C2)Br)C3=CC=NC=C3
|
| InChi Key |
CZQKLBYEPOIHMC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H13BrN4S/c1-20-14(12-6-8-17-9-7-12)18-19-15(20)21-10-11-2-4-13(16)5-3-11/h2-9H,10H2,1H3
|
| Chemical Name |
4-[5-[(4-bromophenyl)methylsulfanyl]-4-methyl-1,2,4-triazol-3-yl]pyridine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 125 mg/mL (346.01 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.76 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.76 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.76 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7681 mL | 13.8404 mL | 27.6809 mL | |
| 5 mM | 0.5536 mL | 2.7681 mL | 5.5362 mL | |
| 10 mM | 0.2768 mL | 1.3840 mL | 2.7681 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
